Joincare Pharmaceutical Group Industry Co.,Ltd. (SHA: 600380)

Joincare Pharmaceutical Group Industry Co.,Ltd. Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Operating Revenue	15,769	16,522	17,013	15,747	13,446	11,903
Other Revenue	124.63	124.63	130.02	157.06	75.73	77.6
Revenue	15,894	16,646	17,143	15,904	13,522	11,980
Revenue Growth (YoY)	-5.29%	-2.90%	7.79%	17.62%	12.87%	6.93%
Cost of Revenue	6,165	6,608	6,380	5,778	4,944	4,320
Gross Profit	9,729	10,039	10,763	10,126	8,577	7,660
Selling, General & Admin	4,919	5,368	5,944	5,966	4,898	4,815
Research & Development	1,487	1,662	1,742	1,397	1,072	905.59
Other Operating Expenses	191.04	177.21	196.72	180.8	161.03	145.97
Operating Expenses	6,597	7,224	7,885	7,553	6,136	5,873
Operating Income	3,132	2,815	2,877	2,572	2,442	1,787
Interest Expense	-135.28	-146.73	-139.02	-90.28	-35.69	-63.1
Interest & Investment Income	477.6	611.73	451.45	263.85	385.8	282.74
Currency Exchange Gain (Loss)	27.25	27.25	104.46	-2.74	-62.35	7.78
Other Non Operating Income (Expenses)	-82.93	-7.69	-9.62	-4.89	-7.72	-4.12
EBT Excluding Unusual Items	3,419	3,300	3,285	2,738	2,722	2,010
Gain (Loss) on Sale of Investments	14.85	-25.42	-76.26	-23.51	10.22	0.53
Gain (Loss) on Sale of Assets	-0.34	-0.17	-0.71	24.04	-7.19	4.51
Asset Writedown	-8.53	-3.27	-31.51	-8.25	-4.18	-3.8
Other Unusual Items	181.68	194.75	280.06	221.66	229.61	166.39
Pretax Income	3,606	3,466	3,456	2,952	2,950	2,178
Income Tax Expense	566.33	614.54	561.8	339.48	371.69	328.08
Earnings From Continuing Operations	3,040	2,851	2,894	2,613	2,578	1,850
Minority Interest in Earnings	-1,569	-1,408	-1,392	-1,284	-1,458	-955.67
Net Income	1,471	1,443	1,503	1,328	1,120	894.35
Net Income to Common	1,471	1,443	1,503	1,328	1,120	894.35
Net Income Growth	0.74%	-3.99%	13.12%	18.57%	25.28%	27.87%
Shares Outstanding (Basic)	1,875	1,903	1,894	1,935	1,948	1,938
Shares Outstanding (Diluted)	1,875	1,907	1,897	1,937	1,956	1,941
Shares Change (YoY)	-2.18%	0.54%	-2.07%	-0.97%	0.76%	18.96%
EPS (Basic)	0.78	0.76	0.79	0.69	0.58	0.46
EPS (Diluted)	0.78	0.76	0.79	0.69	0.57	0.46
EPS Growth	2.98%	-4.51%	15.51%	19.73%	24.33%	7.49%
Free Cash Flow	2,969	2,799	2,830	1,042	2,195	1,609
Free Cash Flow Per Share	1.58	1.47	1.49	0.54	1.12	0.83
Dividend Per Share	0.180	0.180	0.180	0.150	0.150	0.160
Dividend Growth	0%	0%	20.00%	0%	-6.25%	0%
Gross Margin	61.21%	60.31%	62.78%	63.67%	63.44%	63.94%
Operating Margin	19.71%	16.91%	16.78%	16.18%	18.06%	14.92%
Profit Margin	9.25%	8.67%	8.77%	8.35%	8.29%	7.47%
Free Cash Flow Margin	18.68%	16.81%	16.51%	6.55%	16.23%	13.43%
EBITDA	4,297	3,826	3,683	3,167	2,989	2,310
EBITDA Margin	27.04%	22.99%	21.48%	19.91%	22.10%	19.28%
D&A For EBITDA	1,166	1,011	805.34	594.45	546.91	522.53
EBIT	3,132	2,815	2,877	2,572	2,442	1,787
EBIT Margin	19.71%	16.91%	16.78%	16.18%	18.06%	14.92%
Effective Tax Rate	15.70%	17.73%	16.26%	11.50%	12.60%	15.06%
Revenue as Reported	15,894	16,646	17,143	15,904	13,522	11,980

Source: S&P Capital IQ. Standard template. Financial Sources.